Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of BPN14770 in Mild Alzheimer's Disease
jRCT2031210149Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zatolmilast in Alzheimer's disease (AD) (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Change from baseline in ADAS-Cog 13 score at Week 24. Started Jun 2021; status: completed.
02
Drugs
zatolmilast
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031210149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210149.